The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...

Jarez Holz says 2026 will be a strong year for biotech stocks. The Mizuho analyst explained why in a recent CNBC interview.

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Despite a challenging year for equity investors, several mid-cap mutual funds delivered returns of 5-12%. Investors often ...

An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...

The AI bubble debate rages as markets head into 2026. We asked eight top investors what side they're on and where they would ...

As 2026 begins it is time to reflect on 2025, another bearish year for ASX healthcare, and Australia’s leading analysts in ...

From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of ...

These include jobs in high paying growth industries such as finance, biotechnology, and information technology. California is ...